HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (26) Citing Articles via Google Scholar Google Scholar Articles by Kereiakes, D. J. Articles by Krucoff, M. W. Search for Related Content PubMed PubMed Citation Articles by Kereiakes, D. J. Articles by Krucoff, M. W.

Surrogates, substudies, and real clinical end points in trials of drug-eluting stents^*

Dean J. Kereiakes, MD, FACC^,_*,1, Richard E. Kuntz, MD, MSc, Laura Mauri, MD, MSc and Mitchell W. Krucoff, MD, FACC^2,

The Lindner Center for Research & Education at The Christ Hospital and The Ohio Heart Health Center, Cincinnati, Ohio
Divisions of Cardiology and Clinical Biometrics, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
Duke Clinical Research Institute, Duke University, Durham, North Carolina.

View larger version (18K): [in a new window]   Figure 1 Relative risk for major adverse cardiovascular events (MACE) up to nine months in randomized trials of the TAXUS paclitaxel-eluting stent; MACE is composite occurrence of cardiovascular death, myocardial infarction, or target vessel revascularization (see text). MR = moderate release; SR = slow release.